| Summary: | The intense activity within biomedical research has never been so populated and voluminous worldwide. As a consequence, publishing research articles in respected journals in the biomedical field has become a challenging endeavour. As scientists of our time, the search for suitable visibility is a primary goal, not an aesthetic or superfluous option. We are required by the research community, the funding bodies, and society at large, to find the right niche to reach our optimal target audience of colleagues and peers; those with whom to share, discuss and leverage the results from our research and, ultimately, bring it closer to the patients. In this context, I sincerely believe that the founding of Endocrine Oncology in February 2021 was a timely and sound decision. The journal has adequately progressed over these two years, completing the initial technical requirements despite a demanding environment, from the world health threat of the COVID- 19 pandemic to the changes and challenges in the editorial and publishing arena. With Endocrine Oncology’s recent acceptance to PubMed, we now face an exciting period of journal development and consolidation. This is a critical time to define the personality of a journal and transform it into a useful resource for the research community.
|
|---|